tiprankstipranks
Advertisement
Advertisement

ALKS Stock Latest News

Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market
Company AnnouncementsAlkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market
5h ago
ALKS
Alkermes price target raised to $48 from $42 at UBS
PremiumThe Fly
Alkermes price target raised to $48 from $42 at UBS
12h ago
ALKS
Alkermes price target raised to $50 from $45 at Needham
PremiumThe Fly
Alkermes price target raised to $50 from $45 at Needham
18h ago
LLY
ALKS
Alkermes Earnings Call: LUMRYZ Momentum Drives Growth
PremiumCompany Announcements
Alkermes Earnings Call: LUMRYZ Momentum Drives Growth
2d ago
ALKS
Alkermes reports Q1 EPS (40c) vs 13c last year
PremiumThe Fly
Alkermes reports Q1 EPS (40c) vs 13c last year
2d ago
ALKS
Alkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B
PremiumThe FlyAlkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B
2d ago
ALKS
Alkermes plc (ALKS) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Alkermes plc (ALKS) Q1 Earnings Cheat Sheet
5d ago
ALKS
Alkermes: Positive Alixorexton Phase 2 Data in Narcolepsy Type 1 Support Advancement to Phase 3 and Reinforce Buy Rating
Premium
Ratings
Alkermes: Positive Alixorexton Phase 2 Data in Narcolepsy Type 1 Support Advancement to Phase 3 and Reinforce Buy Rating
21d ago
ALKS
Alkermes to present additional data from Vibrance-1 Phase 2 alixorexton study
PremiumThe Fly
Alkermes to present additional data from Vibrance-1 Phase 2 alixorexton study
21d ago
ALKS
Alkermes announces publication of 56-week post hoc analysis of Lybalvi
PremiumThe Fly
Alkermes announces publication of 56-week post hoc analysis of Lybalvi
23d ago
ALKS
Alkermes price target raised to $36 from $34 at BofA
PremiumThe Fly
Alkermes price target raised to $36 from $34 at BofA
28d ago
ALKS
Alkermes price target lowered to $44 from $45 at RBC Capital
PremiumThe Fly
Alkermes price target lowered to $44 from $45 at RBC Capital
1M ago
ALKS
Alkermes management to meet with Piper Sandler
PremiumThe FlyAlkermes management to meet with Piper Sandler
1M ago
ALKS
Alkermes announces initiation of Brilliance Studies
Premium
The Fly
Alkermes announces initiation of Brilliance Studies
1M ago
ALKS
Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink
Premium
The Fly
Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink
1M ago
LLY
ALKS
Centessa acquisition ‘may help rouse’ Alkermes shares, says RBC Capital
PremiumThe Fly
Centessa acquisition ‘may help rouse’ Alkermes shares, says RBC Capital
1M ago
LLY
ALKS
Alkermes jumps after Eli Lilly acquires peer Centessa
PremiumThe Fly
Alkermes jumps after Eli Lilly acquires peer Centessa
1M ago
LLY
ALKS
Alkermes rises 17.7%
PremiumThe Fly
Alkermes rises 17.7%
1M ago
ALKS
Alkermes price target lowered to $43 from $45 at Piper Sandler
PremiumThe Fly
Alkermes price target lowered to $43 from $45 at Piper Sandler
1M ago
TAK
ALKS
Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch
PremiumCompany AnnouncementsAlkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch
2M ago
ALKS
Alkermes’ ALKS 2680 Narcolepsy Study Completion: What Investors Should Watch Next
Premium
Company Announcements
Alkermes’ ALKS 2680 Narcolepsy Study Completion: What Investors Should Watch Next
2M ago
ALKS
Alkermes price target lowered to $43 from $46 at H.C. Wainwright
Premium
The Fly
Alkermes price target lowered to $43 from $46 at H.C. Wainwright
2M ago
ALKS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >